自身免疫疾病在急性间质性肺炎中的作用探索
本研究基于美国MarketScan和Medicare理赔数据(2016-2023)回顾性分析急性间质性肺炎(AIP)住院患者,比较合并与不合并自身免疫疾病者的结局。Medicare队列中合并自身免疫疾病者90天死亡率更低(OR 0.85),出院回家 odds 更高(OR 1.18),出院至专业护理机构 odds 更低(OR 0.77),其他结局无显著差异。
要点
- 合并自身免疫疾病的AIP患者90天死亡率显著更低(OR 0.85,95%CI 0.74-0.99)。
- 合并自身免疫疾病与更高出院回家几率相关(OR 1.18,95%CI 1.02-1.36)。
- 两组在住院时长、复发、机械通气方面无显著差异。
核心结论
- 合并自身免疫疾病的AIP患者90天死亡率更低且出院去向更有利,其他结局相似。
研究设计与样本
- 回顾性队列研究,使用2016-2023年美国MarketScan和Medicare理赔数据,依据ICD-10编码识别诊断。
- 共纳入Medicare 4726例和MarketScan 975例AIP患者,其中20%合并自身免疫疾病。
主要发现
- Medicare队列中,合并自身免疫疾病者90天死亡率OR 0.85(95%CI 0.74-0.99)。
- 合并自身免疫疾病者出院回家OR 1.18(95%CI 1.02-1.36),出院至专业护理机构OR 0.77(95%CI 0.61-0.97)。
- 住院时长、复发、30天内机械通气及MarketScan队列结果在自身免疫状态间无显著差异。
关键数值与推荐
- 90天死亡率OR 0.85(95%CI 0.74-0.99,Medicare队列)。
- 出院回家OR 1.18(95%CI 1.02-1.36,Medicare队列)。
- 出院至专业护理机构OR 0.77(95%CI 0.61-0.97,Medicare队列)。
临床怎么用
- 对合并自身免疫疾病的AIP患者,可关注其可能具有更低的90天死亡风险和更有利的出院去向。
- 自身免疫状态或反映更积极专科诊疗,但需前瞻性研究确认。
局限性
- 回顾性理赔数据研究,可能存在编码偏倚和未测量混杂。
- 部分结局(住院死亡、180天死亡)仅限Medicare队列,MarketScan结果未显示显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical factors influencing outcomes of patients hospitalized with acute interstitial pneumonia (AIP) are not well described because of the condition's rarity. RESEARCH QUESTION: Do patients with AIP and autoimmune conditions differ from patients with AIP without autoimmune conditions in mortality, recurrence, mechanical ventilation, discharge disposition, and length of hospital stay? STUDY DESIGN AND METHODS: This retrospective cohort study used US MarketScan and Medicare claims (2016-2023). Diagnoses were identified using International Classification of Diseases, 10th Revision, codes. Outcomes included in-hospital, 90-day, and 180-day mortality (Medicare only); AIP recurrence; mechanical ventilation within 30 days; discharge disposition; and length of stay. Multivariable logistic and negative binomial regression compared outcomes by autoimmune status, adjusting for demographics and geography. RESULTS: The study included 4,726 patients from Medicare claims and 975 patients from MarketScan claims; 20% had an autoimmune condition. Patients with autoimmune conditions covered by Medicare showed a significantly lower odds of 90-day mortality (OR, 0.85; 95% CI, 0.74-0.99), higher odds of discharge home (OR, 1.18; 95% CI, 1.02-1.36), and lower odds of discharge to a skilled nursing facility (OR, 0.77; 95% CI, 0.61-0.97). Length of stay, recurrence, mechanical ventilation, and results from MarketScan did not differ significantly by autoimmune status. INTERPRETATION: Our results show that patients with AIP and autoimmune conditions covered by Medicare experienced lower 90-day mortality and more favorable discharge disposition, and other outcomes were similar. These differences may reflect a subgroup characterized by greater engagement with specialty care and differential treatment approaches. Future work is needed to identify factors associated with better AIP outcomes to inform more effective care.
引用
- Nikahd M, Small B, Hand BN, et al. Exploring the Role of Autoimmune Conditions in Acute Interstitial Pneumonia. Chest. 2026. PMID: 42612903. doi:10.1016/j.chest.2026.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。